Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study
to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12
months followed by a 6-month open-label extension phase.